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Purpose of the study
Atazanavir is a good but expensive regimen in resource
limited settings (RLS). A previous HIV-NAT study
showed that a low dose of ATV/r 200/100mg once daily
(QD) provided adequate atazanavir plasma concentra-
tions in HIV-infected Thai adults. Reducing the dose
would make atazanavir more accessible to those patients
in need in RLS. We aimed to evaluate long term efficacy
of lower dose ATV/r 200/100 mg in HIV-infected Thai
adults.
Methods
HIV infected patients commencing ATV/r 200/100 mg
QD in a prospective long term cohort at HIV-NAT,
Bangkok, Thailand were analysed. CD4, HIV RNA, and
safety parameters are performed every 6 months as part
of the cohort.
Summary of results
A total of 84 (51% men) subjects with median age of 40
years and median body weight of 57.6 kg were included
in this analysis. The median time of taking lower dose
was 63 (IQR 39-82, range 2-237) weeks. 11/84 subjects
had HIV RNA > 50 copies/mL at time of ATV/r lower
dose initiation. These patients mainly were NNRTI
based treatment failure. 79% used tenofovir as backbone.
High ATV Ctrough (32%), hyperbilirubinemia (32%),
and clinically jaundice (22%) were the main reason for
using the lower dose. At time of analysis, 72/74 (97%)
patients with availability of at least 1 HIV RNA at 6
months interval, had HIV RNA <50 copies/mL. The
median CD4 count was significantly increased from 394
to 456 cells/mm3 (P =0.010). The median change in
fasting cholesterol, triglyceride, LDL and HDL were -6 ,
-11, 13.8 and 4 mg/dL, respectively. However, the
changes were not statistically significant exception for
HDL (p=0.006). In patients previously used standard
dose of ATV/r 300/100 QD, the median of bilirubin was
1.9 (range 0.1-7.7) mg/dl and it improved significantly
after dose reduction (p = 0.003). Majority of the patients
well tolerated to the treatment, only 9 patients, ATV/r
200/100 mg QD was discontinued due to ran out of
stock (4 patients), hepatitis (2 patients), hyperbilirubine-
mia (1), nephrotic syndrome (1), and non-adherence (1).
ATV Ctrough concentrations of ATV/r 200/100 were
available in only 51 cases, all had ATV Ctrough concen-
trations >0.15mg/L.
Conclusions
Regimens with ATV/r 200mg/100mg provided adequate
ATV plasma concentrations, were effective and well tol-
erated in HIV-infected Thai adult patients. A rando-
mized controlled trial should be conducted to confirm
our findings. This data will be benefit to a million of
HIV infected in RLS.
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